Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen. In this combination, with methotrexate and 5-FU administered at standard doses, hematologic toxicity of prednimustine at a dose of 100 mg/m2 orally on Days 1-5 repeated every 4 weeks was acceptable. Nausea and vomiting occurred in 40 of the 47 patients but was only grade 1-2 in 35 of these patients. Only one patient had alopecia to the extent of requiring a wig. Response to treatment could be evaluated in 28 patients; 21 achieved a response (complete or partial lasting a median of 13 months.
D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D002699:Chlorambucil / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D009325:Nausea / Q000139:chemically induced; D010865:Pilot Projects; D011238:Prednimustine / Q000008:administration & dosage* / Q000009:adverse effects; D013629:Tamoxifen / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced
D013629:Tamoxifen; D002699:Chlorambucil; D011238:Prednimustine; D005472:Fluorouracil; D008727:Methotrexate